A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer

PURPOSE: ZEN-3694 is a bromodomain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide (ENZ) was evaluated in a phase 1b/2a study in metastatic castration-resistant prostate cancer (mCRPC). EXPERI...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Aggarwal, Rahul, Schweizer, Michael T., Nanus, David M., Pantuck, Allan, Heath, Elisabeth, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y., Small, Eric J., Abida, Wassim, Alumkal, Joshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572827/
https://ncbi.nlm.nih.gov/pubmed/32694156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1707
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk